Replimune, Inc.
Clinical trials sponsored by Replimune, Inc., explained in plain language.
-
Cancer-fighting virus shows promise in liver cancer trial
Disease control Recruiting nowThis study tests a new treatment called RP2, a virus that attacks cancer cells, alone or with other drugs, in people with advanced liver or bile duct cancer that has not responded to first treatment. About 60 adults will take part. The goal is to see if the combination shrinks tu…
Phase: PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
Virus therapy tested for tough skin cancers in transplant patients
Disease control Recruiting nowThis study is testing an experimental therapy called RP1 for people who have had an organ or bone marrow transplant and now have advanced skin cancer. RP1 is a modified cold sore virus that is injected directly into tumors to try to destroy them and boost the body's immune respon…
Phase: PHASE1, PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Researchers track Long-Term risks of cancer immunotherapy
Knowledge-focused Recruiting nowThis study watches 50 people who already received Replimune's cancer immunotherapy to see if any side effects show up later. Participants are followed for 5 years with no new treatment. The goal is to make sure the therapy is safe over time.
Sponsor: Replimune, Inc. • Aim: Knowledge-focused
Last updated Apr 26, 2026 17:17 UTC